Coagulation biomarkers and prediction of venous thromboembolism and survival in small cell lung cancer: A sub-study of RASTEN - A randomized trial with low molecular weight heparin.
Coagulation activation and venous thromboembolism (VTE) are hallmarks of cancer; however, there is an unmet need of improved biomarkers for individualized anticoagulant treatment. The present sub-study of the RASTEN trial was designed to explore the role of coagulation biomarkers in predicting VTE r...
| Main Authors: | , , , , , , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Public Library of Science (PLoS)
2018-01-01
|
| Series: | PLoS ONE |
| Online Access: | http://europepmc.org/articles/PMC6226210?pdf=render |
| _version_ | 1828784651450187776 |
|---|---|
| author | E Gezelius A Flou Kristensen P O Bendahl Y Hisada S Risom Kristensen L Ek B Bergman M Wallberg U Falkmer N Mackman S Pedersen M Belting |
| author_facet | E Gezelius A Flou Kristensen P O Bendahl Y Hisada S Risom Kristensen L Ek B Bergman M Wallberg U Falkmer N Mackman S Pedersen M Belting |
| author_sort | E Gezelius |
| collection | DOAJ |
| description | Coagulation activation and venous thromboembolism (VTE) are hallmarks of cancer; however, there is an unmet need of improved biomarkers for individualized anticoagulant treatment. The present sub-study of the RASTEN trial was designed to explore the role of coagulation biomarkers in predicting VTE risk and outcome in a homogenous cancer patient population. RASTEN is a multicenter, randomized phase-3 trial investigating the survival effect of low molecular weight heparin enoxaparin when added to standard treatment in newly diagnosed small cell lung cancer (SCLC) patients. Plasma collected at baseline, during treatment, and at follow-up was used in this ad hoc sub-study (N = 242). Systemic coagulation was assessed using four assays reflecting various facets of the coagulation system: Total tissue factor (TF); extracellular vesicle associated TF (EV-TF); procoagulant phospholipids (PPL); and thrombin generation (TG). We found small variations of biomarker levels between baseline, during treatment and at follow-up, and appeared independent on low molecular weight heparin treatment. Overall, none of the measured biomarkers at any time-point did significantly associate with VTE incidence, although increased total TF at baseline showed significant association in control patients not receiving low molecular weight heparin (P = 0.03). Increased TG-Peak was significantly associated with decreased overall survival (OS; P = 0.03), especially in patients with extensive disease. Low baseline EV-TF predicted a worse survival in the low molecular weight heparin as compared with the control group (HR 1.42; 95% CI 1.04-1.95; P = 0.03; P for interaction = 0.12). We conclude that the value of the analyzed coagulation biomarkers for the prediction of VTE risk was very limited in SCLC patients. The associations between TG-Peak and EV-TF with patient survival and response to low molecular weight heparin therapy, respectively, warrant further studies on the role of coagulation activation in SCLC aggressiveness. |
| first_indexed | 2024-12-11T23:35:25Z |
| format | Article |
| id | doaj.art-fc411eef701d46fe82a4b9ad222dfd3f |
| institution | Directory Open Access Journal |
| issn | 1932-6203 |
| language | English |
| last_indexed | 2024-12-11T23:35:25Z |
| publishDate | 2018-01-01 |
| publisher | Public Library of Science (PLoS) |
| record_format | Article |
| series | PLoS ONE |
| spelling | doaj.art-fc411eef701d46fe82a4b9ad222dfd3f2022-12-22T00:45:53ZengPublic Library of Science (PLoS)PLoS ONE1932-62032018-01-011311e020738710.1371/journal.pone.0207387Coagulation biomarkers and prediction of venous thromboembolism and survival in small cell lung cancer: A sub-study of RASTEN - A randomized trial with low molecular weight heparin.E GezeliusA Flou KristensenP O BendahlY HisadaS Risom KristensenL EkB BergmanM WallbergU FalkmerN MackmanS PedersenM BeltingCoagulation activation and venous thromboembolism (VTE) are hallmarks of cancer; however, there is an unmet need of improved biomarkers for individualized anticoagulant treatment. The present sub-study of the RASTEN trial was designed to explore the role of coagulation biomarkers in predicting VTE risk and outcome in a homogenous cancer patient population. RASTEN is a multicenter, randomized phase-3 trial investigating the survival effect of low molecular weight heparin enoxaparin when added to standard treatment in newly diagnosed small cell lung cancer (SCLC) patients. Plasma collected at baseline, during treatment, and at follow-up was used in this ad hoc sub-study (N = 242). Systemic coagulation was assessed using four assays reflecting various facets of the coagulation system: Total tissue factor (TF); extracellular vesicle associated TF (EV-TF); procoagulant phospholipids (PPL); and thrombin generation (TG). We found small variations of biomarker levels between baseline, during treatment and at follow-up, and appeared independent on low molecular weight heparin treatment. Overall, none of the measured biomarkers at any time-point did significantly associate with VTE incidence, although increased total TF at baseline showed significant association in control patients not receiving low molecular weight heparin (P = 0.03). Increased TG-Peak was significantly associated with decreased overall survival (OS; P = 0.03), especially in patients with extensive disease. Low baseline EV-TF predicted a worse survival in the low molecular weight heparin as compared with the control group (HR 1.42; 95% CI 1.04-1.95; P = 0.03; P for interaction = 0.12). We conclude that the value of the analyzed coagulation biomarkers for the prediction of VTE risk was very limited in SCLC patients. The associations between TG-Peak and EV-TF with patient survival and response to low molecular weight heparin therapy, respectively, warrant further studies on the role of coagulation activation in SCLC aggressiveness.http://europepmc.org/articles/PMC6226210?pdf=render |
| spellingShingle | E Gezelius A Flou Kristensen P O Bendahl Y Hisada S Risom Kristensen L Ek B Bergman M Wallberg U Falkmer N Mackman S Pedersen M Belting Coagulation biomarkers and prediction of venous thromboembolism and survival in small cell lung cancer: A sub-study of RASTEN - A randomized trial with low molecular weight heparin. PLoS ONE |
| title | Coagulation biomarkers and prediction of venous thromboembolism and survival in small cell lung cancer: A sub-study of RASTEN - A randomized trial with low molecular weight heparin. |
| title_full | Coagulation biomarkers and prediction of venous thromboembolism and survival in small cell lung cancer: A sub-study of RASTEN - A randomized trial with low molecular weight heparin. |
| title_fullStr | Coagulation biomarkers and prediction of venous thromboembolism and survival in small cell lung cancer: A sub-study of RASTEN - A randomized trial with low molecular weight heparin. |
| title_full_unstemmed | Coagulation biomarkers and prediction of venous thromboembolism and survival in small cell lung cancer: A sub-study of RASTEN - A randomized trial with low molecular weight heparin. |
| title_short | Coagulation biomarkers and prediction of venous thromboembolism and survival in small cell lung cancer: A sub-study of RASTEN - A randomized trial with low molecular weight heparin. |
| title_sort | coagulation biomarkers and prediction of venous thromboembolism and survival in small cell lung cancer a sub study of rasten a randomized trial with low molecular weight heparin |
| url | http://europepmc.org/articles/PMC6226210?pdf=render |
| work_keys_str_mv | AT egezelius coagulationbiomarkersandpredictionofvenousthromboembolismandsurvivalinsmallcelllungcancerasubstudyofrastenarandomizedtrialwithlowmolecularweightheparin AT afloukristensen coagulationbiomarkersandpredictionofvenousthromboembolismandsurvivalinsmallcelllungcancerasubstudyofrastenarandomizedtrialwithlowmolecularweightheparin AT pobendahl coagulationbiomarkersandpredictionofvenousthromboembolismandsurvivalinsmallcelllungcancerasubstudyofrastenarandomizedtrialwithlowmolecularweightheparin AT yhisada coagulationbiomarkersandpredictionofvenousthromboembolismandsurvivalinsmallcelllungcancerasubstudyofrastenarandomizedtrialwithlowmolecularweightheparin AT srisomkristensen coagulationbiomarkersandpredictionofvenousthromboembolismandsurvivalinsmallcelllungcancerasubstudyofrastenarandomizedtrialwithlowmolecularweightheparin AT lek coagulationbiomarkersandpredictionofvenousthromboembolismandsurvivalinsmallcelllungcancerasubstudyofrastenarandomizedtrialwithlowmolecularweightheparin AT bbergman coagulationbiomarkersandpredictionofvenousthromboembolismandsurvivalinsmallcelllungcancerasubstudyofrastenarandomizedtrialwithlowmolecularweightheparin AT mwallberg coagulationbiomarkersandpredictionofvenousthromboembolismandsurvivalinsmallcelllungcancerasubstudyofrastenarandomizedtrialwithlowmolecularweightheparin AT ufalkmer coagulationbiomarkersandpredictionofvenousthromboembolismandsurvivalinsmallcelllungcancerasubstudyofrastenarandomizedtrialwithlowmolecularweightheparin AT nmackman coagulationbiomarkersandpredictionofvenousthromboembolismandsurvivalinsmallcelllungcancerasubstudyofrastenarandomizedtrialwithlowmolecularweightheparin AT spedersen coagulationbiomarkersandpredictionofvenousthromboembolismandsurvivalinsmallcelllungcancerasubstudyofrastenarandomizedtrialwithlowmolecularweightheparin AT mbelting coagulationbiomarkersandpredictionofvenousthromboembolismandsurvivalinsmallcelllungcancerasubstudyofrastenarandomizedtrialwithlowmolecularweightheparin |